Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)

被引：0
|
作者：
Garcia-Manero, Guillermo
Scott, Bart L.
Kishtagari, Ashwin
Sanikommu, Srinivasa R.
Al-Kali, Aref
Lee, Je-Hwan
Burgues, Juan M. Bergua
Diez-Campelo, Maria
Erba, Harry P.
Garcia-Hernandez, Carmen
Santillana, Guillermo Sanz
O'Connell, Casey
Jang, Jun-Ho
Shin, Dong-Yeop
Sayar, Hamid
Rao, Mayank
Schwartz, Richard S.
An, Grace
Jin, Feng
Forgie, Alison J.
Tsiatis, Athanasios C.
Altman, Jessica K.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT060
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT060
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Azacitidine Combination with Lenalidomide in Treating Higher-Risk Myelodysplastic Syndromes: A Single-Center, Phase 2 Trial
    Song, Dandan
    Ge, Zheng
    BLOOD, 2023, 142
  • [32] Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission
    List, A. F.
    Fenaux, P.
    Mufti, G. J.
    Hellstroem-Lindberg, E.
    Gore, S.
    Bennett, J. M.
    Silverman, L. R.
    Backstrom, J.
    Allen, A. R.
    Beach, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] A hemodialysis patient with higher-risk myelodysplastic syndrome treated with standard-dose azacitidine
    Ham, Johanna C.
    Hoogendijk-van den Akker, Judith M.
    Verdonck, Leo F.
    LEUKEMIA & LYMPHOMA, 2012, 53 (12) : 2521 - 2522
  • [34] Treatment of Higher-Risk Myelodysplastic Syndrome
    Garcia-Manero, Guillermo
    SEMINARS IN ONCOLOGY, 2011, 38 (05) : 673 - 681
  • [35] Magrolimab in Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes: 5F9005 Phase 1b Study Results
    Sallman, David A.
    Al Malki, Monzr M.
    Asch, Adam S.
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel A.
    Kambhampati, Suman N.
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Gu, Lin
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol
    Lal, Indu
    Vyas, Paresh
    Daver, Navel
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S20 - S21
  • [36] The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
    Silverman, Lewis R.
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Hellstrom-Lindberg, Eva
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan F.
    Gore, Steven D.
    Seymour, John F.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    BLOOD, 2008, 112 (11) : 91 - 91
  • [37] Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy
    Duong, Vu H.
    Jaglal, Michael V.
    Zhang, Ling
    Kale, Vishakha
    Lancet, Jeffrey E.
    Komrokji, Rami S.
    List, Alan F.
    LEUKEMIA RESEARCH, 2013, 37 (03) : 300 - 304
  • [38] A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes
    Mikkael A. Sekeres
    Michael Schuster
    Magalie Joris
    Jürgen Krauter
    Johan Maertens
    Dimitri Breems
    Emmanuel Gyan
    Tibor Kovacsovics
    Amit Verma
    Paresh Vyas
    Eunice S. Wang
    Keith Ching
    Thomas O’Brien
    Corrado Gallo Stampino
    Weidong Wendy Ma
    Arthur Kudla
    Geoffrey Chan
    Amer M. Zeidan
    Annals of Hematology, 2022, 101 : 1689 - 1701
  • [39] A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
    Sebert, Marie
    Renneville, Aline
    Bally, Cecile
    Peterlin, Pierre
    Beyne-Rauzy, Odile
    Legros, Laurence
    Gourin, Marie-Pierre
    Sanhes, Laurence
    Wattel, Eric
    Gyan, Emmanuel
    Park, Sophie
    Stamatoullas, Aspasia
    Banos, Anne
    Laribi, Kamel
    Jueliger, Simone
    Bevan, Luke
    Chermat, Fatiha
    Sapena, Rosa
    Nibourel, Olivier
    Chaffaut, Cendrine
    Chevret, Sylvie
    Preudhomme, Claude
    Ades, Lionel
    Fenaux, Pierre
    HAEMATOLOGICA, 2019, 104 (08) : 1565 - 1571
  • [40] Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome
    Chien, Kelly S.
    Borthakur, Gautam
    Naqvi, Kiran
    Daver, Naval
    Bravo, Guillermo Montalban
    Cortes, Jorge E.
    DiNardo, Courtney D.
    Jabbour, Elias
    Alvarado, Yesid
    Andreeff, Michael
    Bose, Prithviraj
    Jain, Nitin
    Sheppard, Kimberly
    Klingner-Winton, Cheri
    Pierce, Sherry A.
    Dong, Xiao Qin
    Soltysiak, Kelly A.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2020, 136
12345